Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIANA trial of standardized carboplatin desensitization in ovarian cancer
jRCTs031260545Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Proportion of patients who completed 2 treatment courses. Started Sep 2026; status: recruiting.
02
Drugs
carboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCTs031260545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260545.